Advertisement
Advertisement

RNA

RNA logo

Atrium Therapeutics, Inc. Common Stock

12.11
USD
Sponsored
+0.37
+3.15%
Aug 06, 16:00 UTC -4
Closed
exchange

After-Market

12.13

+0.03
+0.21%

Atrium Therapeutics, Inc. Common Stock Profile

About

Avidity Biosciences Inc. is a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates(TM). The company's AOC platform design, engineer and develop therapeutics which combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies. Its lead product candidate consist AOC 1001, is designed to treat myotonic dystrophy type 1,and other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. Avidity Biosciences Inc. is based in SAN DIEGO.

Info & Links

CEO

Headquarters

--

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

--

Auditor

Share holders

--

Employees

--

Atrium Therapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

207.58M

Enterprise Value

-60.27M

Enterprise Value/EBITDA(ttm)

3.52

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

539.97

Price to Book(mrq)

5.63

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

25.00%

Operating Margin(ttm)

-2634.59%

Profit Margin(ttm)

-21.18%

Return on Equity(ttm)

-37.70%

Return on Invested Capital(ttm)

-7.11%

Return on Assets(ttm)

-33.70%

Income Statement

Revenue(ttm)

19.64M

Revenue Per Share(ttm)

1.15

Gross Profit(ttm)

19.64M

EBITDA(ttm)3

-17.13M

Net Income Available to Common(ttm)

-16.63M

Diluted EPS(ttm)

-4.18

Share Statistics

Beta (5Y Monthly)

0.93

52-Week Change

-68.35%

S&P 500 52-Week Change

21.51%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

17.11M

Dividend Yield

0.00%

Float4

148.81M

% Held by Insiders

3.83%

% Held by Institutions

--

Balance Sheet

Total Cash(mrq)

267.85M

Total Cash Per Share(mrq)

15.66

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

13.04%

Quick Ratio(mrq)

11.57%

Book Value Per Share(mrq)

13.69

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.82

Free Cash Flow(ytd)

-33.24M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement